Status:
COMPLETED
Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)
Lead Sponsor:
Royan Institute
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
25-60 years
Phase:
PHASE1
Brief Summary
This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD).
Detailed Description
We will assess the 18-month safety and potential efficacy of autologous MSCs as a therapy for CKD. A total of 10 patients with CKD IV injection of high doses 2×106/kg of autologous MSCs t, which will ...
Eligibility Criteria
Inclusion
- Male and Female
- CKD symptoms
- CKD confirmed with serum and urine analysis and GFR 25-60 mL/min/1.73 m2
- Patient's age between 25 - 60 years
- Ability to understand and willingness to sign consent from
Exclusion
- Pregnant or lactating
- Basis disease such as diabetes, malignancy and autoimmune
- Unable to follow post-operative exercise regimen or return for evaluations
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT02195323
Start Date
April 1 2014
End Date
January 1 2016
Last Update
January 5 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royan Institute
Tehran, Iran